Jordi Solé-Violán

TL;DR: In this paper, the authors found that auto-antibodies neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections.

TL;DR: Initial use of combination therapy significantly reduces the likelihood of inappropriate therapy, which is associated with higher risk of death, and administration of only one effective antimicrobial or combination therapy provides similar outcomes, suggesting that switching to monotherapy once the susceptibility is documented is feasible and safe.

TL;DR: Combination antibiotic therapy does not seem to increase ICU survival in all patients with severe community-acquired pneumonia, however, in the subset of patients with shock, combination antibiotic therapy improves survival rates.

TL;DR: In intubated patients, pneumonia by A. baumannii is not significantly associated with attributable mortality rate or an increased length of intensive care unit stay.

TL;DR: Despite appropriate glycopeptide therapy, there is an increased attributable mortality for pneumonia by ORSA, after careful adjustment for disease severity and diagnostic category.